O. G. Vilamajó

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, The Lancet.

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.

Khalid Yusoff, Frederick M. Costello, Martin O'Donnell, 2017, Lancet.

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, Lancet.

Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial

G. Guyatt, M. Turiel, S. Yusuf, 2018, The Lancet.

Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data

Pedro F. Campos, Roger A. Nadeau, Jonathan B Sumner, 2021, BMJ.

Acute cardiac rupture during dobutamine-atropine echocardiography stress test.

A. Orlandini, E. Paolasso, E. Tuero, 2000, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

Roger A. Nadeau, Jonathan B Sumner, T. Furukawa, 2022, Clinical Research in Cardiology.

Usefulness of pharmacologic stress echocardiography in a chest pain center.

A. Orlandini, E. Paolasso, E. Tuero, 2000, The American journal of cardiology.

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, Lancet.